Company Description
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products.
It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands.
It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr.
Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio.
The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa.
The company was founded in 1781 and is headquartered in Chuo, Japan.
| Country | Japan |
| Founded | 1781 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 47,029 |
| CEO | So-Young Kim |
Contact Details
Address: 1-1, Nihonbashi-Honcho 2-chome Chuo, 103-8668 Japan | |
| Phone | 81 3 3278 2111 |
| Website | takeda.com |
Stock Details
| Ticker Symbol | TAK |
| Exchange | NYSE |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| CIK Code | 1395064 |
| CUSIP Number | 874060205 |
| ISIN Number | US8740602052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Seigo Izumo | Chair of Management Board |
| Haruhiko Hirate | Member of Management Board |
| Salvatore Alesci M.D., Ph.D. | Member of Management Board and Head of Research & Development Global Science and Biomedical Policy |
| Michael Fox | Chief Operating Officer |
| Norimasa Takeda | Chief Accounting Officer and Corporate Controller |
| Iwaaki Taniguchi | Senior Vice President of Corporate Finance and Controlling Department |
| Gabriele Ricci | Chief Data and Technology Officer |
| Christopher David O'Reilly | Global Head of Investor Relations and Global Finance |
| Giles Platford | President of International Business Unit |
| Dr. Christopher J. Morabito M.D. | Head of Research & Development Pipeline Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 9, 2026 | 6-K | Report of foreign issuer |
| Jul 8, 2026 | 6-K | Report of foreign issuer |
| Jun 29, 2026 | 6-K | Report of foreign issuer |
| Jun 26, 2026 | 6-K | Report of foreign issuer |
| Jun 24, 2026 | 6-K | Report of foreign issuer |
| Jun 24, 2026 | 6-K | Report of foreign issuer |
| Jun 24, 2026 | 6-K | Report of foreign issuer |
| Jun 17, 2026 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Jun 17, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Jun 9, 2026 | 6-K | Report of foreign issuer |